<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03361319</url>
  </required_header>
  <id_info>
    <org_study_id>CCR 4448</org_study_id>
    <nct_id>NCT03361319</nct_id>
  </id_info>
  <brief_title>Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma</brief_title>
  <acronym>N3</acronym>
  <official_title>A Phase I Trial of Combination Nab-Paclitaxel and Nintedanib or Nab-paclitaxel and Placebo in Relapsed Non-Small Cell Lung Cancer Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A PHASE I/II TRIAL OF COMBINATION NAB-PACLITAXEL AND NINTEDANIB OR NAB-PACLITAXEL AND PLACEBO&#xD;
      IN RELAPSED NSCLC ADENOCARCINOMA&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is divided into 2 parts: Part 1 is the Phase Ib portion of the trial and Part 2 is&#xD;
      the Phase II portion of the trial. Once the Trial Steering Committee has completed the dose&#xD;
      limiting toxicity (DLT) assessment for Part 1 and confirmed RP2D for Part 2, Part 2 enrolment&#xD;
      will proceed. The objective(s) for each part are as follows:&#xD;
&#xD;
      Part 1: The objective of Part 1 is to evaluate the safety and tolerability of combination&#xD;
      nab-paclitaxel and nintedanib in patients with stage IIIb and IV adenocarcinoma of the lung&#xD;
      in second and third treatment line setting and to determine the maximum tolerated dose&#xD;
      (MTD)/recommended phase 2 dose (RP2D) of nintedanib when given with nab-paclitaxel at&#xD;
      100mg/m2 d1, d8 q21.&#xD;
&#xD;
      Part 2: The primary objective of Part 2 is to explore the efficacy of combination&#xD;
      nab-paclitaxel and nintedanib versus nab-paclitaxel and placebo in the same patient&#xD;
      population, with nintedanib/placebo given at the recommended phase 2 dose (RP2D) as defined&#xD;
      during part 1 of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawal of financial support from funder&#xD;
  </why_stopped>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part I: A dose-escalation - standard 3+3 design. Part 2: A placebo-controlled, randomised, double-blind, 2-arms.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Part 2 only of the study is double-blinded. 2 arms</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Maximum Tolerated Dose</measure>
    <time_frame>1 and 2 years from patients commencement</time_frame>
    <description>To define Maximum tolerated dose (MTD) and evaluate incidence of dose-limiting toxicities (DLTs) during Cycle 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Adverse Events Review</measure>
    <time_frame>4 years from Start date of trial</time_frame>
    <description>To examine the frequency of all Adverse Events graded by NCI-CTCAE version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: RECIST Response</measure>
    <time_frame>4 years from start date of trial</time_frame>
    <description>To examine the objective tumour response according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cycles Tolerated</measure>
    <time_frame>4 years from start date of trial</time_frame>
    <description>To define the number of cycles of nab-paclitaxel with nintedanib given</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Overall Survival</measure>
    <time_frame>9 months post Chemotherapy</time_frame>
    <description>To examine overall survival in the ITT and predefined subgroups (PD pre/post 9 months from start of first line chemotherapy; prior or no prior immunotherapy).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Part 2: Progression Free Survival</measure>
    <time_frame>12 weeks post first dose of treatment and ongoing until end of study</time_frame>
    <description>To explore PFS rate at 12 weeks from first dose of nab-paclitaxel with nintedanib/placebo</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>NSCLC, Recurrent</condition>
  <condition>Adenocarcinoma of Lung</condition>
  <arm_group>
    <arm_group_label>Part 1: (Phase Ib) Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A dose-finding study of nintedanib (Vargatef) with nab-paclitaxel (Abraxane) with a standard 3+3 design. In the dose escalation part there will be 3 dose cohorts of nintedanib:&#xD;
Dose level -1: 100mg po BID d2-7, 9-21, q21 Dose level 1: 150mg po BID d2-7, 9-21, q21 Dose level 2: 200mg po BID d2-7, 9-21, q21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the dose expansion part, 6 additional patients will be enrolled at the maximum tolerated dose (MTD) of nintedanib (Vargatef) with nab-paclitaxel (Abraxane), prior to proceeding to part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: (Phase II)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo-controlled, randomised, double-blind, 2-arm, phase 2 multi-centre clinical trial of nab-paclitaxel (Abraxane) with nintedanib (Vargatef) and nab-paclitaxel alone.&#xD;
Arm A: nab-paclitaxel + placebo Arm B: nab-paclitaxel + nintedanib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vargatef</intervention_name>
    <description>small molecule triple kinase inhibitor</description>
    <arm_group_label>Part 1: (Phase Ib) Dose Escalation</arm_group_label>
    <arm_group_label>Part 1: Dose Expansion</arm_group_label>
    <arm_group_label>Part 2: (Phase II)</arm_group_label>
    <other_name>Nintedanib</other_name>
    <other_name>L01xe31</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane</intervention_name>
    <description>Paclitaxel formulated as albumin bound nanoparticles</description>
    <arm_group_label>Part 1: (Phase Ib) Dose Escalation</arm_group_label>
    <arm_group_label>Part 1: Dose Expansion</arm_group_label>
    <arm_group_label>Part 2: (Phase II)</arm_group_label>
    <other_name>Paclitaxel</other_name>
    <other_name>L01CD01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo in place of Ninedanib</description>
    <arm_group_label>Part 2: (Phase II)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged 18 or over.&#xD;
&#xD;
          -  Patients with a pathologically confirmed diagnosis of stage IIIb or stage IV&#xD;
             adenocarcinoma of the lung; patients with locally recurrent disease (stage IIIa) and&#xD;
             no radical treatment options are also eligible.&#xD;
&#xD;
          -  Patients who have previously received no more than 2 lines of systemic therapy for&#xD;
             NSCLC with palliative intent:&#xD;
&#xD;
          -  Chemotherapy as first or second line with palliative intent&#xD;
&#xD;
          -  Relapsing within 6 months of adjuvant chemotherapy after surgery or as part of radical&#xD;
             chemo-radiotherapy, which count as one line of therapy&#xD;
&#xD;
          -  Licenced or experimental maintenance therapy is allowed (e.g. pemetrexed)&#xD;
&#xD;
          -  Immunotherapy at prior line of treatment (first or second line) is allowed.&#xD;
&#xD;
          -  Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0-1.&#xD;
&#xD;
          -  Patients with estimated life expectancy of ≥ 12 weeks.&#xD;
&#xD;
          -  Patients with at least one radiologically measurable tumour lesion as defined by&#xD;
             RECIST 1.1 criteria.&#xD;
&#xD;
          -  Patients with adequate haematopoietic, hepatic and renal function.&#xD;
&#xD;
          -  Signed informed consent in accordance with local legislation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a known EGFR kinase sensitising mutation or ALK gene fusion prior to&#xD;
             enrolment who have not received prior TKI (patients enrolled and subsequently found to&#xD;
             be positive will remain on protocol). Patients with known EGFR activating mutation or&#xD;
             ALK fusion who have received appropriate TKI treatment will be allowed.&#xD;
&#xD;
          -  Any concurrent anticancer systemic therapy.&#xD;
&#xD;
          -  Prior treatment with nintedanib or any other VEGFR inhibitor; prior treatment with&#xD;
             bevacizumab is allowed&#xD;
&#xD;
          -  Patients refractory to prior taxane therapy for advanced disease. Prior taxane used in&#xD;
             the adjuvant setting does not exclude eligibility provided there is no disease&#xD;
             recurrence within 12 months upon completion of chemotherapy in that setting.&#xD;
&#xD;
          -  Inadequate laboratory parameters defined by:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt; 1,500/μl (1.5x109/L).&#xD;
&#xD;
          -  Platelets &lt; 100,000/μl (100x109/L).&#xD;
&#xD;
          -  Haemoglobin &lt; 9.0 g/dl or requiring transfusions.&#xD;
&#xD;
          -  Creatinine clearance &lt; 45 ml/min (by local institutional methods).&#xD;
&#xD;
          -  Total bilirubin outside normal limits:&#xD;
&#xD;
          -  ALT and/or AST &gt; 1.5 x ULN in patients without liver metastasis.&#xD;
&#xD;
          -  ALT and/or AST &gt; 2.5 x ULN in patients with liver metastasis.&#xD;
&#xD;
          -  International normalised ratio (INR) &gt; 2, prothrombin time (PT) and partial&#xD;
             thromboplastin time (PTT) &gt; 50% of deviation of institutional ULN.&#xD;
&#xD;
          -  Proteinuria CTCAE grade 2 or greater.&#xD;
&#xD;
          -  Pre-existing peripheral sensory neuropathy CTCAE grade 2 or greater.&#xD;
&#xD;
          -  Use of any investigational drug within 4 weeks of randomisation.&#xD;
&#xD;
          -  Radiotherapy within 4 weeks prior to randomisation.&#xD;
&#xD;
          -  Major surgery (other than biopsy) within 4 weeks prior to randomisation.&#xD;
&#xD;
          -  Active brain metastases or leptomeningeal disease (defined as stable for &lt;4 weeks, no&#xD;
             adequate previous treatment with radiotherapy, symptomatic, requiring treatment with&#xD;
             anti-convulsants; dexamethasone therapy will be allowed if administered as stable dose&#xD;
             for at least 4 weeks prior to randomisation).&#xD;
&#xD;
          -  Any other active current malignancy (other than non-melanomatous skin cancer, in situ&#xD;
             breast or in situ cervical cancer, prostate cancer diagnosed more than 3 years prior,&#xD;
             or breast cancer diagnosed more than 5 year prior to randomisation).&#xD;
&#xD;
          -  Active or uncontrolled infections or serious illnesses or medical conditions that in&#xD;
             the opinion of the investigator could interfere with the patient's participation in&#xD;
             the study, including:&#xD;
&#xD;
          -  Known active or chronic hepatitis C and/or B infection.&#xD;
&#xD;
          -  Known pre-existing interstitial lung disease or pneumonitis&#xD;
&#xD;
          -  Presence of significant cardiovascular diseases (i.e. uncontrolled hypertension,&#xD;
             unstable angina, history of infarction within the past 12 months prior to start of&#xD;
             study treatment, congestive heart failure &gt; NYHA II, serious cardiac arrhythmia,&#xD;
             pericardial effusion).&#xD;
&#xD;
          -  Gastro-intestinal abnormalities, including inability to take oral medication,&#xD;
             requirement for intravenous feeding, active peptic ulcer, prior surgical procedures&#xD;
             affecting absorption, any medical co-morbidity affecting gastrointestinal absorption.&#xD;
&#xD;
          -  History of clinically significant haemorrhagic or thromboembolic event in the past 6&#xD;
             months.&#xD;
&#xD;
          -  Known inherited predisposition to bleeding or thrombosis.&#xD;
&#xD;
          -  Major injuries within the past 10 days prior to start of study treatment with&#xD;
             incomplete wound healing and/or planned surgery during the on-treatment study period.&#xD;
&#xD;
          -  Drug or alcohol abuse.&#xD;
&#xD;
          -  Therapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed&#xD;
             for maintenance of indwelling intravenous device) or anti-platelet therapy (except low&#xD;
             dose therapy with acetylsalicylic acid &lt;325mg her day).&#xD;
&#xD;
          -  Radiographic evidence (CT or MRI) of cavitary or necrotic tumours or local invasion of&#xD;
             major blood vessels by tumour.&#xD;
&#xD;
          -  Pregnancy or breast feeding; female patients must have a negative pregnancy test&#xD;
             (beta-HCG test in urine or serum) prior to commencing study treatment.&#xD;
&#xD;
          -  Patients who are sexually active and unwilling to use a medically acceptable method of&#xD;
             contraception during the trial and for at least three months after ceasing study&#xD;
             therapy (medically acceptable methods of contraception include total true abstinence*,&#xD;
             permanent sterilisation (see section 7.1.4), combined oral, transdermal or&#xD;
             intra-vaginal hormonal contraceptives, methoxyprogesterone injections (e.g.&#xD;
             Depo-provera), copper-banded intra-uterine devices, hormone-impregnated intra-uterine&#xD;
             systems and vasectomised partners; all methods of contraception, with the exception of&#xD;
             total abstinence, should be used in combination with the use of a condom by male&#xD;
             sexual partners).&#xD;
&#xD;
          -  Known hypersensitivity or any contraindications to the trial drugs, including&#xD;
             nab-paclitaxel/nintedanib, to their excipients or to contrast media or other&#xD;
             ingredients including peanuts and soya.&#xD;
&#xD;
          -  Patients unable to comply with the protocol.&#xD;
&#xD;
               -  True abstinence, when this is in line with the preferred and usual lifestyle of&#xD;
                  the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal,&#xD;
                  post-ovulation methods), declaration of abstinence for the duration of exposure&#xD;
                  to IMP, and withdrawal are not acceptable methods of contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Popat</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 22, 2017</study_first_submitted>
  <study_first_submitted_qc>November 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2017</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Adenocarcinoma of lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

